A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
ACTIVE_NOT_RECRUITING
Status
Conditions
- COVID-19
- SARS-COV-2 Infection
Interventions
- BIOLOGICAL: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
Sponsor
BioNTech SE
Collaborators